The FDA recently approved semaglutide (Wegovy) for preventing serious heart conditions in some people, but questions remain about how it works
Briefly

from www.scientificamerican.com1 month ago
The FDA's March 8 announcement will allow doctors to prescribe Novo Nordisk's Wegovy, which has a higher maximum dose of semaglutide than Ozempic...
www.scientificamerican.comhttps://www.scientificamerican.com/article/wegovy-is-first-weight-loss-drug-approved-for-heart-diseases/
The FDA based its decision on a 2023 trial called Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT), in which Novo Nordisk tested Wegovy in more than 17,000 people...
www.scientificamerican.comhttps://www.scientificamerican.com/article/wegovy-is-first-weight-loss-drug-approved-for-heart-diseases/
Read at www.scientificamerican.com
#semaglutide #fda-approval #cardiovascular-disease-prevention #wegovy #bmi-criteria
[
add
]
[
|
|
]